Published in

Oxford University Press, European Heart Journal, 23(42), p. 2265-2269, 2021

DOI: 10.1093/eurheartj/ehab196

Links

Tools

Export citation

Search in Google Scholar

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

Journal article published in 2021 by Jurrien ten Berg ORCID, Dirk Sibbing, Bianca Rocca ORCID, Eric Van Belle, Bernard Chevalier, Jean-Philippe Collet ORCID, Dariusz Dudek, Martine Gilard, Diana A. Gorog ORCID, Julia Grapsa ORCID, Erik Lerkevang Grove ORCID, Patrizio Lancellotti, Anna Sonia Petronio, Andrea Rubboli, Lucia Torracca and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.